fbpx

Day

December 8, 2015
Ness Ziona, Israel - Dec 7, 2015 - Atox Bio, developer of immunomodulatory therapeutics for rapidly-progressing infectious diseases in critically ill patients, today announced that it has enrolled the first patient in its Phase 3 study to evaluate AB103 - the first-ever candidate developed for the treatment of Necrotizing Soft Tissue Infections (NSTIs), also known...

News

Eske Willerslev receives prestigious Norwegian science prize for his Lundbeck Foundation research on brain disorders
22. January 2021
Science Programme Director (Open Neuroplatform)
18. January 2021
Scientific Programme Director (Talent programs)
15. January 2021

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge